These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20704604)

  • 1. Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor.
    Lee EJ; Song R; Park JN; Lee YA; Son JS; Hong SJ; Yang HI; Lee SH
    Int J Rheum Dis; 2010 Aug; 13(3):e16-9. PubMed ID: 20704604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alopecia areata during etanercept therapy.
    Pan Y; Rao NA
    Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept: in ankylosing spondylitis.
    McCormack PL; Wellington K
    BioDrugs; 2004; 18(3):199-205; discussion 206. PubMed ID: 15161337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.
    Tolu S; Rezvani A; Hindioglu N; Calkin Korkmaz M
    Rheumatol Int; 2018 Nov; 38(11):2157-2162. PubMed ID: 30293157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report.
    Cay HF; Gungor HA; Sezer I; Kacar C; Balci N
    J Clin Pharm Ther; 2006 Dec; 31(6):645-8. PubMed ID: 17176371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis.
    Rolle AS; Zimmermann B; Poon SH
    J Clin Rheumatol; 2013 Mar; 19(2):90-3. PubMed ID: 23364662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demyelination during anti-TNFα therapy for ankylosing spondylitis.
    Mercieca C; Vella N; Borg AA
    Mod Rheumatol; 2012 Apr; 22(2):303-7. PubMed ID: 21748364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.
    Cereda CW; Zecca C; Mazzucchelli L; Valci L; Staedler C; Bassetti CL; Gobbi C
    Mult Scler; 2013 May; 19(6):820-3. PubMed ID: 23069873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.